U.S. regulator approves Teva migraine drug, shares rise

(Reuters) – Shares of Israeli drugmaker Teva Pharmaceutical Industries rose over 5 percent in after-hours trading on Friday after the U.S. Food and Drug Administration (FDA) approved the company’s new migraine treatment, a drug Teva has been banking on to help revive its fortunes.

A man walks past the logo of Teva Pharmaceutical Industries at their plant in Jerusalem December 14, 2017. REUTERS/Ammar Awad/File Photo

The wholesale price of the drug, Ajovy, is $575 a month, the same as Aimovig, a similar monthly injection sold by Amgen Inc and Novartis AG that has been available in the…

Read More Here

Be the first to comment on "U.S. regulator approves Teva migraine drug, shares rise"

Leave a comment

Your email address will not be published.